Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Yao-city, Japan Clinical Trials

A listing of Yao-city, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (9) clinical trials

Autologous Cord Blood Cell Therapy for Neonatal Encephalopathy

This is a multicenter pilot study to evaluate the feasibility and safety of intravenous infusions of autologous (the patient's own) umbilical cord blood cells in term gestation newborns with neonatal encephalopathy (hypoxic-ischemic encephalopathy). If a neonate is born with signs of moderate to severe encephalopathy and cooled for the encephalopathy, ...

Phase

5.36 miles

Learn More »

Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

The purpose of this study is to assess the safety and tolerability of itacitinib in combination with corticosteroids in Japanese subjects with Grades II to IV acute graft-versus-host disease (aGVHD).

Phase

5.41 miles

Learn More »

A Phase 1 Study Of Talazoparib PARP Inhibitor In Japanese Patients With Advanced Solid Tumors

This is a Phase 1 study which consists of 2 parts; Dose Escalation part and Expansion part. The dose escalation part is openlabel, and evaluates safety, preliminary efficacy and PK of singleagent talazoparib in sequential cohorts of adult patients with advanced solid tumors who are resistant to standard therapy or ...

Phase

5.79 miles

Learn More »

A Safety and Tolerability Study of INCB054828 in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

The purpose of this study is to evaluate the safety and tolerability of INCB054828 in Japanese subjects with advanced malignancies.

Phase

6.14 miles

Learn More »

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

This study consists of 2 cohorts of the ACM regimen part for Japanese relapsed/refractory AML patients and 1 cohort of the A+7+3 regimen part for Japanese newly diagnosed AML patients. The purpose of this study are as below. To evaluate the safety of DSP-2033 (Alvocidib) in combination with cytarabine/mitoxantrone (ACM ...

Phase

6.6 miles

Learn More »

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Japanese Patients With Unresectable Pancreatic Cancer.

A Phase I, open-label, multi-center study to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in Japanese patients with stage III or IV unresectable pancreatic cancer. Patients with stage IV must failed a gemcitabine based first-line chemotherapy. Patients with stage III will ...

Phase

7.27 miles

Learn More »

Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in participants with breast cancer in the expansion part 1 and adenoid cystic carcinoma (ACC) in ...

Phase

7.27 miles

Learn More »

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).

Phase

8.88 miles

Learn More »

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

This study is an open-label, multicenter, phase 1 study of SyB C-0501 by continuous daily oral administration in patients with advanced solid tumors, who have previously received anticancer therapy and consists of two parts. Part 1 is a dose escalation study to evaluate tolerability of SyB C-0501 in the patients, ...

Phase

8.88 miles

Learn More »